News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • CNTB develops rademikibart to deliver rapid lung-function gains in acute asthma and COPD exacerbations.
  • CNTB market cap ~ $138.5M, shares trade near $2.20 after a $20.2M placement.
  • Company reports about $46M cash on the balance sheet.
  • Upcoming clinical readouts will determine whether rademikibart differentiates from Dupixent.
  • The setup is a binary, high-volatility swing trade; size positions accordingly.
  • Positive readouts could materially re-rate the stock, while negative results would likely cause sharp downside.

Latest Articles

Safe Pro Awarded U.S. Air Force SBIR Contract for AI Dataset Development for Use in Airfield Operations

Safe Pro Awarded U.S. Air Force SBIR Contract for AI Dataset Development for Use in Airfield Operations

Safe Pro Group Inc., a Nasdaq-listed company specializing in AI-enabled defense and security solutions, has been awarded a Small Business Innovation Research (SBIR) contract by AFWERX, the innovation arm of the U.S. Air Force. The contract focuses on developing an AI dataset using images of Foreign Object Debris/Damage encountered in Air Force and …

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026

Voyager Therapeutics announced positive six-month GLP toxicology study results for VY1706, their investigational gene therapy targeting tau protein in Alzheimer's disease. The therapy showed good tolerability and up to 75% sustained tau reduction in key brain regions of non-human primates following a single intravenous dose. With FDA IND clearance …

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection

Aligos Therapeutics announced the completion of enrollment for its global Phase 2 B-SUPREME study testing pevifoscorvir sodium as a treatment for chronic hepatitis B virus (HBV) infection. The study includes both HBeAg positive and negative participants and compares pevifoscorvir monotherapy against tenofovir disoproxil fumarate. Topline safety and…

Qorvo® Recognized by Northrop Grumman with 2026 Supplier Excellence Award for Strategic Excellence

Qorvo® Recognized by Northrop Grumman with 2026 Supplier Excellence Award for Strategic Excellence

Qorvo has been recognized by Northrop Grumman with the 2026 Supplier Excellence Award for Strategic Excellence, highlighting its critical role in providing high-performance RF solutions for next-generation defense systems including aircraft, missile defense, and space platforms. This award underscores the strong strategic partnership between Qorvo …

SEGG Media Drives Revenue With High-Impact Quadrant X Shopify Pop-Up Activation During British Grand Prix Week

SEGG Media Drives Revenue With High-Impact Quadrant X Shopify Pop-Up Activation During British Grand Prix Week

Sports Entertainment Gaming Global Corporation (SEGG Media) successfully executed a high-impact Quadrant x Shopify pop-up event during the 2026 British Grand Prix week in London, attracting over 10,000 fans and generating strong direct-to-consumer merchandise sales. The activation showcased SEGG's ability to convert digital audiences into multiple …

Kratos Receives Approximate $100 Million Sole Source Prime Space Domain Awareness System Program Award

Kratos Receives Approximate $100 Million Sole Source Prime Space Domain Awareness System Program Award

Kratos Defense & Security Solutions has secured an approximate $100 million sole source prime contract to produce a ground-based modular space domain awareness system. The award reflects Kratos' leadership and innovative capabilities in space domain awareness and related national security technologies, positioning the company to play a critical rol…

BetRivers Launches in Alberta, Bringing Its Award-Winning Casino Gaming and Sports Betting Mobile Platform to Players Across the Province

BetRivers Launches in Alberta, Bringing Its Award-Winning Casino Gaming and Sports Betting Mobile Platform to Players Across the Province

Rush Street Interactive (RSI) has launched its BetRivers online casino and sportsbook platform in Alberta, Canada, extending its award-winning and highly rated gaming offerings to a new regulated market. The company aims to deliver premium entertainment and innovative gamified features to Alberta players, complementing its presence in multiple U.S.…

Circle8 Awarded Two $20 Million Dutch Public Sector Contract Extensions, Demonstrating Positive Commercial Momentum Across the Public Sector

Circle8 Awarded Two $20 Million Dutch Public Sector Contract Extensions, Demonstrating Positive Commercial Momentum Across the Public Sector

Circle8 Group, Inc. has successfully extended two major public sector contracts in the Netherlands, with a combined annual value of approximately $20 million. These contract renewals with Waternet and De Bevelanden strengthen Circle8's recurring revenue and underscore its robust commercial momentum in 2026, following multiple other sizable contract…

Apollomics Regains Full Compliance with Nasdaq Listing Requirements

Apollomics Regains Full Compliance with Nasdaq Listing Requirements

Apollomics Inc., a clinical-stage biopharmaceutical company focusing on oncology therapies, announced it has regained compliance with Nasdaq's Market Value of Listed Securities requirement, resolving prior concerns over its market capitalization falling below the minimum $35 million threshold. This reinstatement secures its listing on the Nasdaq Ca…

Tactile Medical Enters Exclusive U.S. Distribution Agreement with ElastiMed for its MyoSleeve™ Wearable Compression Device for VA and DoD Patients

Tactile Medical Enters Exclusive U.S. Distribution Agreement with ElastiMed for its MyoSleeve™ Wearable Compression Device for VA and DoD Patients

Tactile Systems Technology has entered into an exclusive agreement to distribute ElastiMed's MyoSleeve, a wearable compression device for chronic swelling, across U.S. Department of Veterans Affairs and Department of Defense patients. The MyoSleeve offers a discreet, cable-free therapy option suitable for earlier stages of chronic swelling, complem…

Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis

Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis

Enlivex Ltd. announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to Allocetra™, its clinical-stage immunotherapy for treating age-related primary knee osteoarthritis in patients aged 64 and older. This designation enables early FDA engagement, potential accelerated approval, and priority review, supporting faste…

Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes

Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes

Sana Biotechnology announced publication in The New England Journal of Medicine of a peer-reviewed letter detailing 14-month follow-up data from a study of its hypoimmune (HIP)-modified pancreatic islet cell therapy. The data demonstrate safety, immune evasion, and durable insulin production without immunosuppression in type 1 diabetes patients. Sa…

Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004

Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004

Immutep Limited reported mature overall survival data from its INSIGHT-003 Phase I trial involving eftilagimod alfa combined with pembrolizumab and chemotherapy in first-line non-squamous NSCLC patients. The median overall survival reached 30.9 months, outperforming historical benchmarks, particularly benefiting patients with low PD-L1 expression. …

Malibu Boats Refinances Credit Facility on the Strength of Its Balance Sheet, Extending Maturity to 2031

Malibu Boats Refinances Credit Facility on the Strength of Its Balance Sheet, Extending Maturity to 2031

Malibu Boats, Inc. has successfully refinanced its credit facility, replacing the prior agreement with Truist Bank. The new financing structure introduces a $100 million term loan alongside a $250 million revolving credit facility, extending the maturity date from 2027 to 2031. This strategic move enhances the company's financial flexibility to inv…

Bukele Secures Ruling Party Nomination to Seek Third Term

Bukele Secures Ruling Party Nomination to Seek Third Term

El Salvador President Nayib Bukele has been formally nominated by his ruling Nuevas Ideas party to run in the 2027 presidential election. The party said he ran unopposed in its primary. Legal changes approved by allies in Congress in July 2025 removed prior constitutional limits and established provisions allowing indefinite presidential reelection…

Butler National: A Small-Cap Aerospace Compounder Poised to Accelerate

Butler National: A Small-Cap Aerospace Compounder Poised to Accelerate

Butler National (BUKS) is a niche aerospace and services issuer showing accelerating revenue and margin expansion driven by Avcon and Butler-Tempe. Recent FAA Supplemental Type Certificates and a $37.0M backlog create a clear revenue runway. This trade idea lays out entry, stop and target for a long trade over a 180-trading-day horizon while highli…

BofA Opens Coverage on Ionos, Sees Double-Digit EPS Compound Through 2028

BofA Opens Coverage on Ionos, Sees Double-Digit EPS Compound Through 2028

BofA Global Research has initiated coverage of Ionos Group SE with a buy rating and a €37 price objective, implying roughly 29% upside from the stock's most recent close of €28.60. The bank projects Ionos will deliver about 8% revenue compound annual growth between 2025 and 2028 and roughly 17% adjusted EPS compounding over the same period. Valuati…